Table 3 displays a comparison of APOE-ε4 carriers and non-carriers in each group. A post-hoc analysis indicated that APOE-ε4 carriers in the LMCI and AD groups had considerably reduced volumes of the NBM and amygdala than non-carriers. This evidence concerns the gene APOE and Alzheimer disease.